Skip to content
Apollo Hospitals logo

Apollo Hospitals Enterprise

APOLLOHOSP NSE
₹8,599.50 +159.50 (+1.89%)
P/E
59.18
View as Markdown
MCP
Close 4 Nov 2026 ₹8,599.50 +817.50 +10.5% 1Y
Start ₹7,782.00

Key Fundamentals

LargecapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.40%
Debt to Equity
0.90
EPS (TTM)
₹145.32
Book Value
₹659.33
Market Cap
—
P/E (TTM)
59.18
P/B
13.04
ROE
21.20%
Dividend Yield
0.24%
EBITDA
₹3,961 Cr
52W High
₹9,070.50
52W Low
₹6,696.50
Day Range
₹8,429.50 – ₹8,599.50
Volume
5,35,919

Peer Comparison

Healthcare › Healthcare Services › Hospitals › Hospital

Apollo Hospitals peer comparison
Apollo Hospitals (this company)
₹8,599.5059.18₹1,22,850 Cr13.040.24%21.20%17.40%₹26,430 Cr₹2,171 Cr
Max Healthcare Institute
₹927.1561.89₹89,301 Cr7.960.22%14.70%14.70%₹8,712 Cr₹1,457 Cr
Manipal Health Enterprises
₹667.2088.96₹86,479 Cr5.340.00%6.64%8.30%₹11,400 Cr₹906 Cr
Aster DM Healthcare
₹719.55117.00₹59,927 Cr14.910.44%11.30%11.60%₹4,876 Cr₹363 Cr
Fortis Healthcare
₹790.6556.96₹59,706 Cr6.030.13%11.20%13.40%₹9,506 Cr₹1,070 Cr
Narayana Hrudayalaya
₹1,931.5048.36₹39,090 Cr7.890.24%20.50%15.50%₹9,072 Cr₹816 Cr
Global Health
₹1,402.0067.76₹37,618 Cr9.520.04%15.20%17.40%₹4,683 Cr₹552 Cr
Median 7 companies₹927.1561.89₹59,927 Cr7.960.22%14.70%14.70%₹9,072 Cr₹906 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

41 Weak

Data confidence 100/100

Category scores

Quality
51
Average
Returns, margins, earnings quality 22% weight
Valuation
38
Weak
Cheap vs sector & own history 24% weight
Growth
48
Average
Sales & profit trajectory 9% weight
Financial Health
25
Poor
Solvency, leverage, coverage 9% weight
Momentum
25
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 76.2% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 17.7%

Weaknesses

2
  • Stock is trading at 12.0 times its book value
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4213
OscillatorsBearish423
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
63.13
Neutral
MACD (12,26,9)
16.41
Bullish
SMA (50)
8,417.19
Bullish
SMA (200)
8,112.65
Bullish

As of

Analyst Rating

Based on 27 analysts
BUY85%

23 of 27 analysts rate Buy, 3 Hold, 1 Sell.

As of

BUY
23
85%
HOLD
3
11%
SELL
1
4%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+15.16%
5Y+19.03%
3Y+14.94%
1Y+15.76%
TTM+17.21%

Net profit

Net profit growth by window
10Y+23.90%
5Y+71.00%
3Y+33.39%
1Y+33.09%
TTM+33.19%

Operating cash flow

Operating cash flow growth by window
10Y+16.94%
5Y+17.69%
3Y+27.53%
1Y+33.71%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+3.86 pp
5Y+4.18 pp
3Y+2.55 pp
1Y+1.06 pp
TTM+0.98 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹7,256 Cr
Mar 2018₹8,243 Cr
Mar 2019₹9,617 Cr
Mar 2020₹11,247 Cr
Mar 2021₹10,560 Cr
Mar 2022₹14,663 Cr
Mar 2023₹16,612 Cr
Mar 2024₹19,059 Cr
Mar 2025₹21,794 Cr
Mar 2026₹25,228 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹131 Cr
Mar 2018₹60.00 Cr
Mar 2019₹200 Cr
Mar 2020₹432 Cr
Mar 2021₹137 Cr
Mar 2022₹1,108 Cr
Mar 2023₹844 Cr
Mar 2024₹935 Cr
Mar 2025₹1,505 Cr
Mar 2026₹2,003 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹1,173 Cr +1.6% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 3 Nov 2026
AI opinion · based on fundamentals
Risk medium

Apollo Hospitals Enterprise Ltd trades at ₹8,440 as of 2026-11-03 with a market cap of ₹1,20,096 crore. The company has delivered strong profit growth of 76% CAGR over five years and maintains an ROE of 20.08%, but carries a premium valuation at 58.08x trailing earnings and 12.8x book value.

Bull Case 8
  • Exceptional 5-year compounded profit growth of 76% CAGR demonstrates strong earnings momentum and operating leverage across the hospital network
  • TTM profit growth of 34% indicates the earnings trajectory remains robust even on a larger base
  • ROE of 20.08% and ROCE of 19.79% as of 2026-11-03 reflect efficient capital deployment for a capital-intensive healthcare services business
  • ROE has improved from a 10-year average of 13% to 21% last year, signalling a structural improvement in profitability rather than a one-off spike
  • Compounded sales growth of 15% over 10 years and 17% TTM shows durable top-line expansion across economic cycles
  • Consistent dividend payout ratio of 17.7% indicates the company returns cash to shareholders while still funding growth
  • 10-year stock price CAGR of 19% reflects sustained long-term wealth creation for shareholders
  • 3-year compounded profit growth of 32% alongside 3-year sales growth of 15% suggests margin expansion is supplementing revenue growth
Bear Case 8
  • Trailing PE of 58.08x as of 2026-11-03 is significantly elevated, leaving little room for execution missteps before a de-rating
  • Price-to-book ratio of 12.8x means the stock trades at a steep premium to its net asset base, which is unusual even for quality franchises
  • Debt-to-equity ratio of 0.90 is notable for a business with heavy capex requirements in hospital infrastructure, adding financial risk
  • Potential capitalisation of interest costs could overstate reported profitability and asset values, flattering both ROE and ROCE metrics
  • Dividend yield of just 0.24% offers negligible income support at the current price of ₹8,440
  • The stock sits roughly 7% below its 52-week high of ₹9,070.50, yet about 26% above its 52-week low of ₹6,696.50, indicating the market is pricing in continued optimism
  • 1-year stock CAGR of 0% suggests recent returns have stalled despite strong underlying profit growth, pointing to possible valuation fatigue
  • 5-year stock CAGR of 13% lags the 5-year profit CAGR of 76%, implying much of the earnings improvement was already anticipated by the market at an earlier stage

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Apollo Hospitals delivered a strong Q2FY27 with 32% YoY profit growth and 23% revenue expansion, driven by robust Healthcare Services performance. The specialty hospital divestment at ₹15,500 million EV sharpens focus on core operations. The key near-term risk is leadership transition following the departure of the President & CEO. If the new management team executes smoothly, the growth trajectory remains firmly positive.

Headwinds 1
  • Senior leadership transition Nov 04

    Three new Senior Management Personnel were appointed to replace the outgoing President & CEO, introducing near-term execution uncertainty during the leadership changeover.

Positives 3
  • Strong Q2FY27 profit growth Nov 04

    Consolidated PAT rose 32% YoY to ₹630 crore in Q2FY27, while revenue grew 23% YoY to ₹7,615 crore and EBITDA increased 29% YoY to ₹1,191 crore.

  • Healthcare Services momentum Nov 04

    Core Healthcare Services segment revenue increased 23% YoY to ₹3,900 crore in Q2FY27, reflecting strong hospital utilization and demand.

  • Specialty hospitals divestment done Nov 04

    Divestment of specialty hospitals to Kids Clinic India was completed at an enterprise value of ₹15,500 million, unlocking capital for redeployment into core operations.

Neutral 1
  • Q2FY27 results announced Nov 04

    Apollo Hospitals reported Q2FY27 consolidated results with 23% revenue growth and 32% PAT growth, alongside completion of a specialty hospital divestment and a senior management restructuring.

Quarterly Results

₹ Cr
APOLLOHOSP quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
4,418
4,847
4,851
4,944
5,086
5,589
5,527
5,592
5,842
6,304
6,477
6,606
7,044
Expenses
3,909
4,219
4,237
4,303
4,410
4,774
4,765
4,822
4,990
5,362
5,512
5,594
5,951
Operating Profit
509
628
614
640
675
816
762
770
852
941
965
1,011
1,092
OPM %
12%
13%
13%
13%
13%
15%
14%
14%
15%
15%
15%
15%
16%
Other Income
34
26
29
37
49
44
69
72
54
61
48
54
62
Interest
106
111
113
119
116
118
110
115
108
110
113
119
120
Depreciation
167
163
167
190
177
184
185
211
215
218
219
224
235
PBT
270
379
363
368
430
557
536
516
583
675
682
722
799
Tax %
36%
34%
30%
30%
27%
29%
29%
20%
24%
27%
24%
24%
24%
Net Profit
173
249
254
258
316
396
379
414
441
494
516
551
610
EPS (₹)
11.59
16.2
17.06
17.65
21.23
26.34
25.89
27.1
30.1
33.19
34.93
36.81
40.39

Profit & Loss

₹ Cr
APOLLOHOSP profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
5,129
6,150
7,256
8,243
9,617
11,247
10,560
14,663
16,612
19,059
21,794
25,228
26,430
Expenses
4,392
5,465
6,522
7,442
8,548
9,656
9,420
12,474
14,548
16,665
18,761
21,449
22,420
Operating Profit
737
684
734
801
1,070
1,591
1,140
2,189
2,065
2,394
3,033
3,779
4,010
OPM %
14%
11%
10%
10%
11%
14%
11%
15%
12%
13%
14%
15%
15%
Other Income
47
92
60
24
26
222
103
368
75
123
222
207
226
Interest
118
180
257
295
327
533
449
379
381
449
458
450
462
Depreciation
212
264
314
359
396
620
573
601
615
687
758
876
896
PBT
455
332
222
171
373
660
221
1,578
1,144
1,380
2,039
2,661
2,877
Tax %
29%
29%
41%
65%
47%
34%
38%
30%
22%
32%
26%
25%
—
Net Profit
335
235
131
60
200
432
137
1,108
844
935
1,505
2,003
2,172
EPS (₹)
24.43
16.99
15.88
8.44
16.96
32.7
10.46
73.42
56.97
62.5
101
135
145
Div. Payout %
24%
35%
38%
59%
35%
18%
29%
16%
26%
26%
13%
15%
—

Balance Sheet

₹ Cr
APOLLOHOSP balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
70
70
70
70
70
70
72
72
72
72
72
72
Reserves
3,102
3,262
3,244
3,182
3,264
3,270
4,531
5,551
6,126
6,864
8,140
9,408
Borrowings
1,992
2,834
3,125
3,427
3,673
3,596
4,160
4,068
4,332
5,333
7,864
8,493
Other Liabilities
1,296
1,195
1,665
1,917
2,159
4,354
2,629
3,570
3,886
4,474
4,568
4,210
Total Liabilities
6,459
7,360
8,103
8,596
9,166
11,289
11,392
13,261
14,416
16,742
20,644
22,183
Fixed Assets
3,244
3,997
4,591
4,773
4,982
7,432
6,778
8,296
8,520
9,664
10,988
12,272
CWIP
533
562
347
712
822
236
234
46
610
873
921
1,032
Investments
311
352
406
352
462
434
1,343
816
574
986
2,487
2,179
Other Assets
2,372
2,448
2,759
2,759
2,901
3,187
3,037
4,104
4,712
5,219
6,248
6,700
Total Assets
6,459
7,360
8,103
8,596
9,166
11,289
11,392
13,261
14,416
16,742
20,644
22,183

Cash Flow

₹ Cr
APOLLOHOSP cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
470
597
623
537
905
1,293
1,265
1,696
1,377
1,920
2,136
2,856
Investing
−759
−888
−1,152
−405
−711
−289
−880
−747
−857
−1,537
−3,383
−2,145
Financing
392
330
477
−108
−215
−910
−340
−792
−633
−311
1,319
−478
Net Cash Flow
103
39
−52
24
−20
94
44
158
−113
72
73
233
Free Cash Flow
−396
−393
−46
−84
233
782
984
1,044
252
785
439
925
CFO/EBITDA
77
108
103
83
103
100
108
87
85
100
86
92

Ratios

APOLLOHOSP financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
43
36
38
37
39
33
46
44
49
48
51
50
Inventory Days
50
49
47
51
46
49
16
21
17
17
16
15
Days Payable
59
66
51
55
56
60
74
79
82
88
72
63
Cash Conversion Cycle
34
19
34
33
29
22
−12
−14
−16
−23
−6
3
Working Capital Days
24
16
27
8
−3
−8
−4
5
−1
−19
−6
−25
ROCE %
12%
9%
8%
7%
10%
14%
8%
17%
14%
15%
17%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Apollo Hospitals insights

64 extracted metrics across FY00–FY27.

Shareholding Pattern

As of Sep 2026

  • FIIs 43.18%
  • Promoters 28.02%
  • DIIs 22.07%
  • Public 4.46%
  • Others 2.03%
  • Government 0.23%

2.91% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Apollo Hospitals Enterprise

What does Apollo Hospitals Enterprise Ltd do?
Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country.
Where is Apollo Hospitals Enterprise Ltd (APOLLOHOSP) listed?
Apollo Hospitals Enterprise Ltd trades as APOLLOHOSP on the NSE and under code 508869 on the BSE.
Which sector does Apollo Hospitals Enterprise Ltd belong to?
Apollo Hospitals Enterprise Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the PE ratio of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd trades at a PE ratio of 59.18 as of 4 Nov 2026, on earnings per share of ₹145.32, against a book value of ₹659.33 per share.
What is the 52-week high and low of Apollo Hospitals Enterprise Ltd?
Over the last 52 weeks Apollo Hospitals Enterprise Ltd has traded between ₹6,696.5 and ₹9,070.5 as of 4 Nov 2026.
Does Apollo Hospitals Enterprise Ltd pay dividends?
Apollo Hospitals Enterprise Ltd has a dividend yield of 0.24%.
What is the Return on Equity (ROE) of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd reported a return on equity of 21.20%. Its debt-to-equity ratio is 0.90.

Company Information

Apollo Hospitals was established in 1983 by Dr. Prathap C Reddy, renowned architect of modern healthcare in India. As the nation’s first corporate hospital, Apollo Hospitals is acclaimed for pioneering the private healthcare revolution in the country. Apollo Hospitals has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several Retail Health models.

Website apollohospitals.com
CEO Dr. Prathap Chandra Reddy FCCP, FICA, FRCS, M.D., MBBS
Employees 42,497
Listed 10 Jan 1996
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/APOLLOHOSP.md for Apollo Hospitals Enterprise Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month